Shin Nippon Biomedical Laboratories (SNBL) is a leading Japanese contract research organization (CRO) providing non-clinical and clinical drug development services to pharmaceutical and biotech companies, operating across Japan, the United States, Asia, and Cambodia. The company also pursues a Translational Research (TR) business centered on its proprietary intranasal drug delivery platform technology (SMART), which has generated spin-out companies including Satsuma Pharmaceuticals (whose intranasal migraine treatment AtzumiTM received FDA approval in April 2025) and SNLD for Parkinson's disease. Additionally, SNBL operates the Mediapolis business in Ibusuki, Kagoshima, encompassing binary geothermal power generation and wellness-focused hotel facilities.
Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.
Free Demo (No Time Limit, 10 Companies) →Shin Nippon Biomedical Laboratories (SNBL) is a leading Japanese contract research organization (CRO) providing non-clinical and clinical drug development services to pharmaceutical and biotech companies, operating across Japan, the United States, Asia, and Cambodia. The company also pursues a Translational Research (TR) business centered on its proprietary intranasal drug delivery platform technology (SMART), which has generated spin-out companies including Satsuma Pharmaceuticals (whose intranasal migraine treatment AtzumiTM received FDA approval in April 2025) and SNLD for Parkinson's disease. Additionally, SNBL operates the Mediapolis business in Ibusuki, Kagoshima, encompassing binary geothermal power generation and wellness-focused hotel facilities.
Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.
Free Demo (No Time Limit, 10 Companies) →